IMS to follow drug wholesaler's decision over information supplies.

Published: 2003-09-08 06:58:00

Updated: 2003-09-08 06:58:00

The Pharmaceutical Business Development Council (PBDC) earlier decided not to supply any drug sales informations to Zuellig. In this connection, IMS Health Korea, who is allegedly connected with Zuellig, replied to the PBDC's question to IMS on the subject of information data supplies to Zuellig ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK